TLRs in plasma cells could potentially affect cellular sensitivity to pharmacological substances by inducing resistance to therapeutic agents; thus, we investigated the capacity of TLR4 to abrogate BTZ [a proteasome inhibitor, that is central to multiple myeloma treatment in the clinic38] activity in MM cells. Here, TLR4 is linked to plasma cell myeloma.